ESTRO 2024 - Abstract Book


Clinical - CNS

ESTRO 2024

Hospital, Department of Radiation Oncology, ACQUAVIVA DELLE FONTI, Italy. 4 LUM University, Department of Medicine and Surgery, CASAMASSIMA, Italy


Hypofractionated radiation therapy (HF-RT) schedules may have radiobiological, patient convenience and healthcare resource advantages over conventionally fractionated radiation therapy (CF-RT) in glioblastoma (GBM). We report outcomes of GBM patients treated with HF-RT and CF-RT.


From January 2021 to April 2023, patients with IDH-wildtype GBM treated with HF-RT (52.5Gy/15 fractions) or CF-RT (60Gy/30 fractions)were selected. Volumetric modulated arc therapy were performed for all patients. Concomitant temozolomide (75mg/mq/die) and adjuvant chemotherapy (TMZ 150-200 mg/mq/5 days q 28) were administered. Overall survival (OS) and progression-free survival (PFS) were estimated using the Kaplan-Meier method.


Ninty-nine patients were treated (HF-RT:53, CF-RT:46). For both HF-RT and CF-RT groups, median age was 65 and 54 years and median KPS was 70%. All patients received concurrent/adjuvant temozolomide. No acute or late neurological side effects of grade ≥ 2 were reported during RT. Grade 3 -4 hematologic toxicity occurred in five cases. At 12 months median follow-up (range 2-28), median OS was 14 months for HF-RT and CF-RT (p NS), and median PFS was 6 and 8 months, respectively.


HF-RT may offer equivalent outcomes and reduce treatment burden compared to CF-RT in GBM patients. Surely, robust data are needed to change the standard approach

Keywords: Glioblastoma, Hypofractionation


Digital Poster

Clinical outcome and dosimetric feasibility of hippocampal sparing whole brain radiotherapy

Bhuvana J, Ankita Parikh, Suryanarayan Kunikullaya U

Gujarat Cancer and Research Institute, B J Medical college, Radiation Oncology, Ahmedabad, India

Made with FlippingBook - Online Brochure Maker